APHS 

APHS is a specific and covalent COX-2 inhibitor with neuroprotective effects. COX-2 is a prostaglandin (PG) synthetase overexpressed in colorectal cancer (CRC) and has pleiotropic cancer-promoting effects. APHS modifies COX-2 by acetylating the active site (serine 516), thereby inhibiting prostaglandin production. The neuroprotective activity of APHS is inhibited by prostaglandin E2. APHS also co-inhibits the WNT pathway, an anti-tumor mechanism in addition to COX-2 inhibition^[1][2].

APHS (10 μM, 30 μM; 0.5 h and 3 h, respectively) protects neuronal cells from NMDA (HY-17551) in a time and concentration-dependent manner^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

262.37

C₁₅H₁₈O₂S

209125-28-0

Liquid

Colorless to light yellow

CCCCC#CCSC1=CC=CC=C1OC(C)=O

Room temperature in continental US; may vary elsewhere.

Solution, -20°C, 2 years

• [1]. Carlson NG. Neuroprotection of cultured cortical neurons mediated by the cyclooxygenase-2 inhibitor APHS can be reversed by a prostanoid. J Neurosci Res. 2003 Jan 1;71(1):79-88.  [Content Brief]

  [2]. Humar B, McNoe L, Dunbier A, Heathcott R, Braithwaite AW, Reeve AE. Heterogeneous gene expression changes in colorectal cancer cells share the WNT pathway in response to growth suppression by APHS-mediated COX-2 inhibition. Biologics. 2008 Jun;2(2):329-37.  [Content Brief]